Patient-specific tumor neoantigen presented by major histocompatibility complex

Patient-specific tumor neoantigen presented by MHC complex" refers to **peptide fragments that arise from mutations unique to an individual patient’s tumor (neoantigens), which are processed and displayed on the surface of cancer cells by major histocompatibility complex (MHC) molecules**. These complexes are recognized by T cell receptors (TCRs), allowing the immune system to specifically target and destroy tumor cells expressing these novel 'non-self' antigens while sparing normal tissues[1][2][3][4]. Neoantigens are not a single protein or defined biological receptor, but a highly diverse group of antigenic peptides resulting from tumor-specific genetic alterations—including point mutations, gene fusions, or aberrant post-translational modifications—and their subsequent presentation by MHC-I or MHC-II[1][2][3]. Because each patient’s neoantigen landscape is unique, these targets are the foundation for personalized immunotherapies (such as neoantigen vaccines or adoptive T cell transfer), promising improved specificity and reduced off-target effects in cancer treatment. However, as a class, "patient-specific tumor neoantigens presented by MHC complexes" is not a single molecular target but rather a dynamic, heterogeneous set of peptide–MHC presentations defined per patient and tumor context[3][4]. **Note on naming:** - This target refers to a class of molecular targets (patient-specific peptides) rather than a unique protein or standard receptor. - It is not incorrect per se, but does not correspond to a single, standardized druggable protein/receptor in the conventional sense[3]. - If structured classification is strictly needed, this is best coded as "Other (neoantigen/MHC complex)" or represented as "Patient-specific tumor neoantigen presented by major histocompatibility complex".

Other names

NeoantigenTumor neoantigenPatient-specific neoantigen

Elicitation of T cell response against cancer cells via recognition of neoantigen–MHC complexes; Targeted cytolysis of tumor cells by T cells; Indirect potentiation of immune activation (when used with checkpoint blockade)